Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non‐Diabetic Adults: A Narrative Review
Open Access
- 27 March 2026
- journal article
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Abstract
Background and Aims: The rising global prevalence of obesity has catalyzed the development of potent glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non‐diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts. Methods: Using information from PubMed, Scopus, and Web of Science, a thematic synthesis was carried out under the guidance of the SANRA procedural framework (2019–2025). The search used tirzepatide as a comparative benchmark and a particular Boolean string to target semaglutide efficacy in non‐diabetic groups. To evaluate metabolic effects and practical obstacles, data from 27 studies including observational studies, randomized controlled trials (RCTs), and qualitative reports, were analytically combined. Results: In adults without diabetes, semaglutide (2.4 mg) shows better weight loss efficacy, with mean reductions of roughly 14.9% as opposed to 9.6% in diabetic groups. Significant improvements in cardiometabolic indicators and quality‐of‐life assessments were observed in addition to weight loss. Nevertheless, the main reason for stopping is still gastrointestinal side effects. Long‐term therapeutic utility is greatly impacted by practical obstacles, such as high out‐of‐pocket expenses, worldwide supply limitations, and the possibility of weight gain after cessation. Conclusion: Although semaglutide is a novel obesity disease‐modifying medication, its effectiveness depends on how well it is incorporated into multimodal treatment plans. Even though its effectiveness has been shown, equitable public health implementation requires addressing structural issues and safety concerns, such as drug pricing models and insurance coverage. Long‐term durability studies and head‐to‐head trials with next‐generation incretins should be the top priorities for future research.Keywords
This publication has 36 references indexed in Scilit:
- Medications for ObesityJAMA, 2024
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialNature Medicine, 2024
- Time to unshackle the medical treatment of obesity in the NHSClinical Medicine, 2024
- Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight LossJAMA Network Open, 2024
- Healthcare professionals’ perceptions and experiences of obesity and overweight and its management in primary care settings: a qualitative systematic reviewPrimary Health Care Research & Development, 2024
- Recent advances in the treatment of type 2 diabetes mellitus using new drug therapiesThe Kaohsiung Journal of Medical Sciences, 2024
- Basal metabolic rate using indirect calorimetry among individuals living with overweight or obesity: The accuracy of predictive equations for basal metabolic rateClinical Nutrition ESPEN, 2024
- Glucagon‐like peptide agonists: A prospective reviewEndocrinology, Diabetes & Metabolism, 2023
- Semaglutide for weight management in adultsPrescriber, 2023
- The Psychology of Behavior Change: A Neglected but Necessary Aspect of Obesity ManagementGastro Hep Advances, 2023